SGD Pharma confirms that JIC (China Jianyin Investment Ltd) is the group’s new shareholder.
JIC, long-term investor with USD 57 billion under management, will allow SGD Pharma to focus on its development and investment plans as part of its growth global strategy.
The new shareholder, whose investment portfolio covers various businesses and geographical zones (Europe, Asia, Australia…), strongly supports SGD Pharma’s management in its industrial and strategical plans.
SGD Pharma is pleased to share with JIC the same ambitions and growth long term objectives aimed at strengthening the company’s position as a global key supplier on the parenteral market.
For more information about JIC, please visit www.jicinv.com